Guides

GLP-1 drugs like Ozempic and life insurance underwriting

How insurers weigh GLP-1 drugs such as Ozempic and Wegovy, what reinsurers have published about weight regain and mortality, and how to prepare an application.

4LifeInsurance · Published October 4, 2026

Taking a GLP-1 drug such as Ozempic, Wegovy, Mounjaro or Zepbound does not by itself rule out life insurance, and it is not a fixed rate-class penalty. Insurers treat the drug as one piece of your health picture: why you take it (diabetes or weight), how long you have taken it, how much weight you lost, and whether your other numbers improved. How each company weighs those factors differs, and the industry's approach is still changing.

What the drugs are and why underwriters care

GLP-1 receptor agonists are prescription medicines that mimic a gut hormone to lower blood sugar and reduce appetite. Semaglutide is sold as Ozempic (type 2 diabetes) and Wegovy (obesity); tirzepatide, which also acts on a second hormone pathway, is sold as Mounjaro and Zepbound. Because underwriting is a prediction of how long you are likely to live, an insurer asks three things about any drug:

  • What condition is it treating? A prescription for type 2 diabetes is underwritten as diabetes (see life insurance with type 1 or type 2 diabetes). A prescription for weight management is underwritten against your build and related conditions such as high blood pressure or sleep apnea.
  • Is the benefit durable? A drug that works only while you take it creates a different risk than a permanent change.
  • Is anything else going on? Rapid weight loss can come from treatment, but an underwriter also checks that it is not caused by an undiagnosed illness.

What reinsurers have published

Reinsurers back many life insurers' policies and publish research that insurers use. The following are documented, dated statements; individual insurers decide for themselves how to apply them.

  • Munich Re (study published February 12, 2026, covering 41 million lives with prescription and mortality data from 2015 to 2025) reported that GLP-1 drugs may drive 0.2% to 0.5% of annual mortality improvement, realized over a 20-year period. It found that among non-diabetic users, mainly people taking the drugs for weight loss, only about 40% were still on the drug after one year, and fewer than 30% among ages 30 to 40, against about 60% for people with diabetes. It cautioned that insurers risk both overestimating risk for people who stay on treatment and underestimating it for those whose treatment is inconsistent, and said electronic health records can help assess adherence. Munich Re's report is the source.
  • Swiss Re (reported by Reinsurance News on April 16, 2025) warned that up to two-thirds of lost weight could be regained after patients stop the drugs, particularly without lasting changes in diet, exercise and sleep. It also pointed to muscle and bone density loss as long-term concerns and encouraged insurers to ask more targeted application questions. See Reinsurance News.

Neither statement is an instruction to charge more or less. Both point at the same underwriting questions: Are you still taking the drug, and is the result holding?

How this plays out in an application

Practice varies by insurer and changes as companies gather experience, so treat the following as typical considerations rather than rules.

  • Disclosure. The application will ask about current and past prescriptions. A prescription database check can also show fills for a GLP-1 drug, so leaving it off is a mistake that can cost you coverage later (see how insurers check your prescription history).
  • Which build counts. Some underwriters use your current weight, some look at your weight before treatment, and some weigh the two, particularly when the loss is recent. A longer period at a stable lower weight generally makes the lower number more credible. The build chart guide covers the basics.
  • Time on the drug. Someone who started a month ago looks different from someone who has been stable for two years.
  • Related conditions. Improved blood pressure, cholesterol and blood sugar readings, documented by your doctor, can help. A history of eating disorders, gallbladder or pancreas problems, or rapid unexplained loss can lead to questions.
  • The reason for the drug. Diabetes is underwritten with its own factors (A1C trend, complications, duration).

Preparing to apply

  1. Gather your records. Ask your prescriber for the start date, dose history, starting and current weight and recent labs (blood pressure, A1C, cholesterol, liver and kidney tests).
  2. Be accurate on the application. Report your actual current height and weight, drug name, start date and diagnosis. Material misstatements can allow an insurer to contest a claim during the the two-year contestability period.
  3. Consider timing. If you are mid-way through weight loss, some people wait until their weight has been stable for a while, because many insurers weigh stability. Waiting has a cost, since age, health and coverage gaps matter, and an agent who works with several insurers can tell you how each treats recent loss. Do not skip needed coverage just to chase a better class.
  4. Compare more than one insurer. Because approaches differ, the same file can come back with different rate classes.
  5. Revisit later. If you are rated higher now and your weight and health stay stable, ask about reconsideration (see asking for a better rate class later).

A hypothetical example

Say a 45-year-old started a weight-management GLP-1 drug 14 months ago, lost 60 pounds and has normal blood pressure and labs that were elevated before treatment. One insurer might underwrite on the current weight. Another might give weight to the starting weight, or ask for a longer stable period. The numbers and outcomes here are illustrative, not predictions; the point is that two carriers can reasonably differ.

Other things to know

Key takeaways

  • A GLP-1 prescription is not an automatic decline or a fixed surcharge; insurers look at the reason for the drug, your results and how stable they are.
  • Munich Re (February 2026) reported possible long-run mortality improvement but low one-year adherence among non-diabetic users; Swiss Re (April 2025) warned that much lost weight can return after stopping.
  • Disclose the drug accurately: prescription databases can reveal it, and misstatements can create claim problems.
  • Carriers differ, so get quotes from more than one and bring documentation of your weight history and labs.

Terms used in this guide

Underwriting The process an insurer uses to evaluate an applicant's risk, from health and lifestyle to finances, and decide whether and at what price to offer coverage. Build chart An insurer's table of height and weight ranges that maps an applicant's body size to the rate classes they can qualify for. Rate class The underwriting category, such as preferred plus, standard or substandard, that sets the price an insurer charges for a given age and coverage. Prescription database check An underwriting search of pharmacy records that shows insurers which medications an applicant has filled, used to verify or flag health history. Reinsurance Insurance that insurance companies buy, passing part of the risk on policies they've sold to another company called a reinsurer. Mortality improvement The long-term decline in death rates at each age over time, which actuaries project forward when pricing life insurance, annuities and pensions.

Latest on this topic